[Plasmacytoma and support therapy with calcitonin]

Area of Science:

• Oncology
• Pharmacology
• Bone Metabolism

Background:

• Multiple myeloma is a cancer of plasma cells, often leading to bone lesions and pain.
• Effective long-term management of multiple myeloma symptoms, particularly bone disease and pain, remains a clinical challenge.
• Calcitonin is a hormone involved in calcium regulation and bone metabolism.

Observation:

• A female patient with multiple myeloma received a two-year course of calcitonin (Miacalcic Sandoz).
• The patient experienced significant pain relief, previously requiring opioid analgesics.
• Pre-treatment mobility was limited, requiring assistance to walk.

Findings:

• The calcitonin treatment demonstrated excellent therapeutic effects over two years.
• The patient regained the ability to walk unaided and discontinued analgesic use.
• Minimal progression of bone affection was noted during a subsequent two-and-a-half-year follow-up period.

Implications:

• Calcitonin may be an effective therapeutic option for managing bone complications in multiple myeloma.
• This case highlights the potential for calcitonin to improve quality of life by reducing pain and enhancing mobility.
• Further research into calcitonin's role in multiple myeloma bone disease is warranted.